Biomedical Instrumentation Engineer - Rapid, On-Demand Testing

University of Utah; Salt Lake City (UT); In loco; USD 60.000 - 100.000; Tempo pieno

Descrizione del lavoro

University of Utah is seeking an Instrument Development Engineer to join our ARPA-H GIVE program. You will help develop an all-in-one testing platform for rapid quality control and lot release, collaborating with clinicians, researchers, and partners to ensure safety and regulatory compliance.

You will design and optimize biomedical devices, conduct risk analyses, and contribute to IP generation and verification, with opportunities to influence next‑gen RNA‑based medicines.

Competenze

• Bachelor's degree in engineering, mathematics, or related scientific field.
• Experience designing and building instruments or devices.
• Ability to conduct risk analyses and document design work.

Mansioni

• Develop unmet needs and translate voice of the customer into design inputs.
• Ideate, develop, and document designs, test methods, and manufacturing processes.
• Create test protocols for benchtop, in vitro, and in vivo testing and write reports.
• Perform risk analyses per applicable standards and support regulatory submissions.
• Collaborate with physicians, researchers, manufacturers, and partners.

Conoscenze

Instrument design

Hardware testing

CAD

Bench debugging

Subsystem integration

Risk management

Python

Data analysis

Formazione

Bachelor's degree in engineering, mathematics, or related scientific field

Strumenti

CAD software

Lab data acquisition

Fabrication techniques

Descrizione del lavoro

University of Utah is seeking an Instrument Development Engineer to join our ARPA-H GIVE program. You will help develop an all-in-one testing platform for rapid quality control and lot release, collaborating with clinicians, researchers, and partners to ensure safety and regulatory compliance.

You will design and optimize biomedical devices, conduct risk analyses, and contribute to IP generation and verification, with opportunities to influence next‑gen RNA‑based medicines.